<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04406649</url>
  </required_header>
  <id_info>
    <org_study_id>STS101-003</org_study_id>
    <nct_id>NCT04406649</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine</brief_title>
  <acronym>ASCEND</acronym>
  <official_title>An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Satsuma Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Satsuma Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study STS101-003 is a multi-center, multiple dose (PRN), open-label, 12-month study to
      evaluate the safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute
      treatment of migraine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ASCEND trial is a multi-center, multiple dose (PRN), open-label, 12-month study to
      evaluate the safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute
      treatment of migraine.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Incidence of adverse events, incidence of abnormal physical examination findings, abnormal 12-lead ECG readings and incidence of nasal symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Freedom</measure>
    <time_frame>Up to 48 hours post-dosing</time_frame>
    <description>Proportion of subjects free from headache pain (defined as moderate or severe headache pain becoming none on a 4-point scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Most-Bothersome Symptom</measure>
    <time_frame>Up to 48 hours post-dosing</time_frame>
    <description>Proportion of subjects free from most bothersome symptom (MBS) among photophobia, phonophobia and nausea</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Migraine</condition>
  <condition>Migraine With Aura</condition>
  <condition>Migraine Without Aura</condition>
  <arm_group>
    <arm_group_label>STS101 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STS101 (dihydroergotamine nasal powder), low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STS101 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STS101 (dihydroergotamine nasal powder), high dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dihydroergotamine</intervention_name>
    <description>Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.</description>
    <arm_group_label>STS101 High Dose</arm_group_label>
    <arm_group_label>STS101 Low Dose</arm_group_label>
    <other_name>Dihydroergotamine Mesylate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Males or females, 18-65 years of age at the time of Screening Visit

          -  Subject has at least 1-year history of migraines (with or without aura), according to
             the

          -  International Classification of Headache Disorder, 3rd Edition (ICHD3)

        Key Exclusion Criteria:

          -  Pregnant or breast-feeding women

          -  Women of child-bearing potential not using or not willing to use highly effective
             contraception.

          -  Diagnosis of headache conditions other than migraine with or without aura, including
             diagnosis of basilar or hemiplegic migraines or cluster headache.

          -  History of coronary artery disease, coronary artery vasospasm (including
             Printz-metals' angina), clinically significant arrhythmia or, peripheral vascular
             disease, ischemic disease (e.g. Raynaud's syndrome, ischemic bowel syndrome, angina
             pectoris, myocardial infarction, or documented silent ischemia); percutaneous coronary
             intervention, or cardiac surgery.

          -  History of cerebrovascular disease, including but not limited to stroke, transient
             ischemic attack, cerebral hemorrhage, subarachnoid hemorrhage.

          -  Diagnosis of major depression with current symptoms, psychosis, alcohol abuse or
             dependence, drug abuse or dependence, major psychiatric conditions (e.g.
             schizophrenia, psychosis or Bipolar disorder), dementia. Other significant
             neurological or psychiatric disorders (including other pain syndromes or risk of
             suicide) that in the opinion of the investigator might interfere with study
             participation and assessments or subject safety.

          -  Any clinically significant symptoms or conditions, including but not limited to
             central nervous system (e.g., seizures), cardiac, pulmonary, metabolic, renal, hepatic
             or gastrointestinal conditions or history of such conditions that, in the opinion of
             the investigator might interfere with study assessments or safety of participant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Detlef Albrecht, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Satsuma Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Manager</last_name>
    <phone>6508370799</phone>
    <email>clin.inquiries@satsumarx.com</email>
  </overall_contact>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 20, 2020</study_first_submitted>
  <study_first_submitted_qc>May 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2020</study_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dihydroergotamine</keyword>
  <keyword>dihydroergotamine mesylate</keyword>
  <keyword>migraine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Migraine with Aura</mesh_term>
    <mesh_term>Migraine without Aura</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dihydroergotamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

